An ICP focused on corporate venture capital, with a diverse team using business learnings and insights from this year to help Debiopharm capitalize on the strategic value of its investments.

The International Consulting Project is at full speed here at IMD. Two out of three client presentations are already behind us, and the team is putting everything we have learned this year into practice, as a preparation to go back to the real corporate world in the following year.

Our team has a truly diverse background, as it brings together five nationalities and experiencse from a wide range of industries and functions: Emma has background in venture capital, Yuki and Simone in industrial product management, Marios comes from the technology startup world, and finally myself from the energy sector. We are guided by professor Patrick Reinmoeller as our faculty coach. When it comes to managing innovation, he is a true reference point for us and his advice is already proving to be invaluable.

Digital technology is redefining the rules of the game in many industries, and and the pharmaceutical industry is no exception. One of the ways of venturing into new technologies in the pharmaceutical industry is through corporate venture capital. Our project is focused on how the client can leverage the strategic value of its corporate venture capital unit to ensure the application of learnings from the investments.

As a team we realized that the ICP is perhaps the most important and challenging exercise of the MBA program. It provides us with an opportunity to apply creative, out-of-the-box thinking and combine it with learnings from the program. This would not be possible without the sincere engagement and openness of Debiopharm’s management team, which has wholeheartedly supported us on this journey.

By Matija Milotic

Team: Yuki Endo, Simone Grancini, Marios Codos, Emma Wang and Matija Milotic

2 Like